Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Drugs for DM
| Question | Answer |
|---|---|
| Stimuli for Insulin Secretion | Glucose, Amino Acids (esp. leucine, arginine), Sulfonyl urea drugs, Vagal stimulation (acetylcholine on M3 receptors) |
| Mechanism for Insulin Release | ^ Glucose -> ^ATP in beta cells -> closure of ATP-dependent K channels -> depolarisation of cell membrane -> Ca channels open -> influx of Ca -> trigger insulin release. |
| Actions of insulin | ^ glycogenesis in liver and muscles, decreases glycogenolysis and lipolysis. ^lipogenesis in adipose tissue, ^ activity of GLUT-4 transporters. |
| Types of insulin replacement (7) | Insulin lispro, Insulin aspart, Insulin glulisine, Regular insulin, Neutral protamine Hagedorn (Isophane), Insulin detemir, Insulin glargine. |
| Insulin lispro | Rapidly acting drug with a short duration (3-6h) which can be administered IV & mixed with other insulin drugs (eg. NPH). Available as Humalog Pen and administered subcutaneously 15min before a meal. |
| Insulin aspart | Rapidly acting drug with short duration (4-5h), can be administered IV & mixed with other insulin drugs (NPH). Available as NovoRapid Flexpen & administered 15min before a meal. |
| Insulin glulisine | Rapidly acting drug with a short duration (1.5h) which can be administered IV & mixed with other insulin drugs (eg. NPH). Administered subcutaneously 15min before a meal or 20 min after, as it appears in blood earlier with higher conc than reg insulin. |
| Regular insulin | Short duration(5-8h) & slower acting (. Can be administered IV and mixed with other insulin (NPH) at varying concentrations for different patients (Mixtard). |
| Neutral Protamine Hagedorn (NPH)/Isophane | Intermediate duration (~15h) and usually mixed with short duration insulin. Has an added component protamine to form dipole prep w/ insulin, releasing it slowly. Have varying pre-mixed preperations. |
| Insulin detemir | Intermediate duration (12-24h), available as Levamir Flexpen. Contains a fatty acid side chain which enhances affinity to plasma albumin. This provides a delayed, reproducible absorption. |
| Insulin glargine | Long duration (>20h), given once daily. |
| Adverse effects of insulin | Hypoglycemia, lipodystrophy (lipoatrophy or lipohypertrophy). Factitious hypoglycemia in non-diabetics who inject a high dose of insulin. Redness at injection site |
| Sulfonylureas: mode of action | Increases secretion of insulin by causing depolarisation of K+ channels in pancreatic B cells, promoting insulin release. |
| Sulfonylureas: examples | 1st gen: tolbutamide, 2nd gen: glibenclamide, glipizide. 3rd gen: glimepiride |
| Sulfonylureas: toxicity | GIT related (nausea, cramps, diarrhea), dizziness, hypoglycemia, occasional rash (due to sulphur), teratogenicity in animals. Drug interation with salicylates. |
| Meglitinide: mode of action | Same as sulfonylureas, just different receptors bound |
| Meglitinide: toxicity | Headache, hypoglycemia. |
| Meglitinide: example | Repaglinide, not commonly used. |
| Biguanide: mode of action | Insulin sensitiser, increases insulin receptor density and sensitivity at tissue level, effect dependent on circulating insulin. Also: stimulates glycolysis, hepatic gluconeogenesis, decreased glucose absorp from GIT, reduced plasma glucagon. |
| Biguanide: clinical uses | main drug for type 2 DM, also reduces hyperlipidemia. mixed with rosiglitazone (thiazolidinedione, another insulin sensitiser. (Avandamet). |
| Biguanide: toxicity | GIT related (nausea,anorexia,diarrhea,vomiting), metallic taste, folate and vB12 def -> pernicious anemia (treated w supplements), lactic acidosis due to inhibition of hepatic gluconeog (seen by hypervent, myalgia, malaise). |
| Biguanide: contraindications | liver disease, due to the reduced ability to undergo gluconeogenesis and breakdown lactic acid (a substrate), excessive alcoholism and shock. |
Created by:
Aurorahx
Popular Pharmacology sets